Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis
Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis
复制标题
接受溃疡性结肠炎治疗的母亲所生孩子中英夫利昔单抗生物仿制药的血清水平
DOI：
10.1093/ibd/izac111
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Ryuichi Okamoto
中科院分区：
文献类型：
--
作者：
Ami Kawamoto;Toshimitsu Fujii;Ryuji Mitani;Yasuhiro Suzuki;Tsunehito Yauchi;Ryuichi Okamoto
英夫利昔单抗生物仿制药CT-P13用于治疗溃疡性结肠炎。我们首次报道了在整个妊娠期间接受CT-P13治疗的患者的血清药物水平和儿童的长期健康状况。
Lay SummaryThe infliximab biosimilar CT-P13 is used for the treatment of ulcerative colitis. We report for the first time the serum drug levels and long-term health status of the child of a patient treated with CT-P13 throughout her pregnancy.